vs
Side-by-side financial comparison of KOSS CORP (KOSS) and Taysha Gene Therapies, Inc. (TSHA). Click either name above to swap in a different company.
Taysha Gene Therapies, Inc. is the larger business by last-quarter revenue ($5.5M vs $2.9M, roughly 1.9× KOSS CORP). KOSS CORP runs the higher net margin — -19.8% vs -507.8%, a 488.0% gap on every dollar of revenue. On growth, Taysha Gene Therapies, Inc. posted the faster year-over-year revenue change (171.3% vs -19.6%). Over the past eight quarters, Taysha Gene Therapies, Inc.'s revenue compounded faster (26.8% CAGR vs 4.2%).
Koss Corporation is a company in Milwaukee, Wisconsin, US that manufactures headphones. The company created the first high-fidelity stereo headphones in 1958.
Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company specializing in developing adeno-associated virus (AAV)-based gene therapies for rare monogenic central nervous system disorders with high unmet medical needs. Its core pipeline targets serious life-threatening neurological conditions, with primary operations and market focus across North America and European regions.
KOSS vs TSHA — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.9M | $5.5M |
| Net Profit | $-565.4K | $-27.9M |
| Gross Margin | 29.0% | — |
| Operating Margin | -35.5% | -516.0% |
| Net Margin | -19.8% | -507.8% |
| Revenue YoY | -19.6% | 171.3% |
| Net Profit YoY | -700.6% | -48.3% |
| EPS (diluted) | $-0.06 | $-0.08 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.9M | $5.5M | ||
| Q3 25 | $4.1M | $0 | ||
| Q2 25 | $3.1M | $2.0M | ||
| Q1 25 | $2.8M | $2.3M | ||
| Q4 24 | $3.6M | $2.0M | ||
| Q3 24 | $3.2M | $1.8M | ||
| Q2 24 | $2.9M | $1.1M | ||
| Q1 24 | $2.6M | $3.4M |
| Q4 25 | $-565.4K | $-27.9M | ||
| Q3 25 | $243.7K | $-32.7M | ||
| Q2 25 | $-232.7K | $-26.9M | ||
| Q1 25 | $-316.7K | $-21.5M | ||
| Q4 24 | $94.1K | $-18.8M | ||
| Q3 24 | $-419.5K | $-25.5M | ||
| Q2 24 | $-110.4K | $-20.9M | ||
| Q1 24 | $-313.8K | $-24.1M |
| Q4 25 | 29.0% | — | ||
| Q3 25 | 40.0% | — | ||
| Q2 25 | 36.0% | — | ||
| Q1 25 | 39.0% | — | ||
| Q4 24 | 39.5% | — | ||
| Q3 24 | 36.6% | — | ||
| Q2 24 | 40.4% | — | ||
| Q1 24 | 31.9% | — |
| Q4 25 | -35.5% | -516.0% | ||
| Q3 25 | -1.1% | — | ||
| Q2 25 | -14.2% | -1347.1% | ||
| Q1 25 | -18.7% | -930.5% | ||
| Q4 24 | -4.0% | -985.8% | ||
| Q3 24 | -19.9% | -1448.4% | ||
| Q2 24 | -11.0% | -1915.4% | ||
| Q1 24 | -23.1% | -713.3% |
| Q4 25 | -19.8% | -507.8% | ||
| Q3 25 | 6.0% | — | ||
| Q2 25 | -7.5% | -1353.6% | ||
| Q1 25 | -11.4% | -935.2% | ||
| Q4 24 | 2.6% | -929.0% | ||
| Q3 24 | -13.1% | -1427.5% | ||
| Q2 24 | -3.8% | -1882.0% | ||
| Q1 24 | -11.9% | -705.4% |
| Q4 25 | $-0.06 | $-0.08 | ||
| Q3 25 | $0.03 | $-0.09 | ||
| Q2 25 | $-0.02 | $-0.09 | ||
| Q1 25 | $-0.03 | $-0.08 | ||
| Q4 24 | $0.01 | $-0.07 | ||
| Q3 24 | $-0.05 | $-0.10 | ||
| Q2 24 | $-0.01 | $-0.09 | ||
| Q1 24 | $-0.03 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $15.5M | $319.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $30.3M | $246.9M |
| Total Assets | $36.8M | $343.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $15.5M | $319.8M | ||
| Q3 25 | $16.5M | $297.3M | ||
| Q2 25 | $15.7M | $312.8M | ||
| Q1 25 | $13.0M | $116.6M | ||
| Q4 24 | $9.7M | $139.0M | ||
| Q3 24 | $11.9M | $157.7M | ||
| Q2 24 | $14.9M | $172.7M | ||
| Q1 24 | $9.9M | $124.0M |
| Q4 25 | $30.3M | $246.9M | ||
| Q3 25 | $30.9M | $219.0M | ||
| Q2 25 | $30.6M | $248.7M | ||
| Q1 25 | $30.7M | $55.1M | ||
| Q4 24 | $31.0M | $71.5M | ||
| Q3 24 | $30.8M | $88.8M | ||
| Q2 24 | $31.1M | $108.9M | ||
| Q1 24 | $31.1M | $53.8M |
| Q4 25 | $36.8M | $343.3M | ||
| Q3 25 | $37.7M | $316.6M | ||
| Q2 25 | $37.2M | $333.3M | ||
| Q1 25 | $37.3M | $138.4M | ||
| Q4 24 | $37.4M | $160.4M | ||
| Q3 24 | $38.1M | $180.2M | ||
| Q2 24 | $37.2M | $200.4M | ||
| Q1 24 | $37.6M | $153.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-760.8K | $-26.7M |
| Free Cash FlowOCF − Capex | $-1.1M | — |
| FCF MarginFCF / Revenue | -37.5% | — |
| Capex IntensityCapex / Revenue | 10.9% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-546.7K | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-760.8K | $-26.7M | ||
| Q3 25 | $762.6K | $-24.2M | ||
| Q2 25 | $-534.9K | $-20.2M | ||
| Q1 25 | $370.4K | $-22.0M | ||
| Q4 24 | $-252.0K | $-18.3M | ||
| Q3 24 | $201.6K | $-21.6M | ||
| Q2 24 | $-174.0K | $-21.5M | ||
| Q1 24 | $328.6K | $-19.8M |
| Q4 25 | $-1.1M | — | ||
| Q3 25 | $761.5K | $-24.3M | ||
| Q2 25 | $-541.8K | — | ||
| Q1 25 | $306.2K | — | ||
| Q4 24 | $-314.3K | $-18.3M | ||
| Q3 24 | $-155.6K | $-21.6M | ||
| Q2 24 | $-174.8K | $-21.7M | ||
| Q1 24 | $269.3K | $-19.9M |
| Q4 25 | -37.5% | — | ||
| Q3 25 | 18.7% | — | ||
| Q2 25 | -17.6% | — | ||
| Q1 25 | 11.0% | — | ||
| Q4 24 | -8.8% | -905.5% | ||
| Q3 24 | -4.9% | -1210.9% | ||
| Q2 24 | -6.0% | -1951.9% | ||
| Q1 24 | 10.2% | -584.5% |
| Q4 25 | 10.9% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.2% | — | ||
| Q1 25 | 2.3% | — | ||
| Q4 24 | 1.8% | 0.1% | ||
| Q3 24 | 11.2% | 2.0% | ||
| Q2 24 | 0.0% | 18.1% | ||
| Q1 24 | 2.3% | 4.1% |
| Q4 25 | — | — | ||
| Q3 25 | 3.13× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -2.68× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
